Interview with Sue Fletcher PYC CSO, page-6

The perpetual moves between 15 and 13 cents will only be interupted by news, I would suspect, or the accumulating entity
revealing its name, it has been going on for months now.

As mentioned by the CEO, a very large OZ biotech investor vastly differs in ways to accumulate stocks, that is how far our CEO
was prepared to go in his comments. In contrast, the US based investors and DPs are not prepared to buy on market, so I guess our
OZ based investor is and continues to do so with the ever reoccuring trading patterns.

Once that entity is revealed, retail investors here will follow, driving price up to go for a second round of US based investment talks from a much higher SP to negotiate from a position of strength.
The last round of talks in the US were conducted with a SP below 500 mil MC.
This is hardly representing anything but our first ocular program, so we will have to wait for evaluations of our extended ocular and
platform valuations including early indicators for CNS and kidney.


My personal guess is that our next talks in the US will be from a 30 to 35 cents base.

all IMO